Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 18 of 18 publications.

Pe M, Alanya A, Falk RS, Amdal CD, Bjordal K, Chang J, Cislo P, Coens C, Dirven L, Speck RM, Fitzgerald K, Galinsky J, Giesinger JM, Holzner B, Le Cessie S, O'Connor D, Oliver K, Pawar V, Quinten C, Schlichting M, Ren J, Roychoudhury S, Taphoorn MJB, Velikova G, Wintner LM, Griebsch I, Bottomley A, SISAQOL-IMI Consortium. Setting international standards in analyzing patient-reported outcomes and quality of life endpoints in cancer clinical trials-innovative medicines nitiative (SISAQOL-IMI): stakeholder views, objectives, and procedures. Lancet Oncol. 2023 Jun;24(6):e270-83. doi: 10.1016/S1470-2045(23)00157-2

Motzer R, Porta C, Alekseev B, Rha SY, Choueiri TK, Mendez-Vidal MJ, Hong SH, Kapoor A, Goh JC, Eto M, Bennett L, Wang J, Pan JJ, Saretsky TL, Perini RF, He CS, Mody K, Cella D. Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study. Lancet Oncol. 2022 Jun;23(6):768-80. doi: 10.1016/S1470-2045(22)00212-1

Navratil-Strawn J, Hartley S, MacLeod S, Lindsay A. The effect of a customized advocacy product on downstream medical expenditures and utilization. Telehealth and medicine today. 2021 Jan;6(2). doi: 10.30953/tmt.v6.250

Standaert B, Van Vlaenderen I, Van Bellinghen LA, Talbird SE, Hicks K, Carrico J, Buck PO. Constrained optimization for the selection of influenza vaccines to maximize the population benefit: a demonstration project. Appl Health Econ Health Policy. 2019 Nov 22. doi: 10.1007/s40258-019-00534-y

Turner EE, Jenks M, McCool C, Marshall C, Millar L, Wood H, Peel A, Craig J, Sims AJ. The Memokath-051 stent for the treatment of ureteric obstruction: a NICE medical technology guidance. Appl Health Econ Health Policy. 2018 Aug;16(4):445-64. doi: 10.1007/s40258-018-0389-3

Barbieri M, Weatherly HL, Ara R, Basarir H, Sculpher M, Adams R, Ahmed H, Coles C, Guerrero-Urbano T, Nutting C, Powell M. What is the quality of economic evaluations of non-drug therapies? A systematic review and critical appraisal of economic evaluations of radiotherapy for cancer. Appl Health Econ Health Policy. 2014 Oct;12(5):497-510. doi: 10.1007/s40258-014-0115-8

Karve S, Markowitz M, Fu DJ, Lindenmayer JP, Wang CC, Candrilli SD, Alphs L. Assessing medication adherence and healthcare utilization and cost patterns among hospital-discharged patients with schizoaffective disorder. Appl Health Econ Health Policy. 2014 Jun;12(3):335-46.

Henk HJ, Kaye JA, Rothman KJ, Becker LK, Legg JC, Li X. Variation by age in neutropenic complications among patients with cancer receiving chemotherapy. Community Oncol. 2013 Jan 1;10(1):16-26.

Earnshaw SR, Graham J, Oleen-Burkey M, Castelli-Haley J, Johnson K. Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis. Appl Health Econ Health Policy. 2009 Jun 1;7(2):91-108.

Davis KL, Mitra D, Kotapati S, Ibrahim R, Wolchok JD. Direct economic burden of high risk and metastatic melanoma: evidence from the SEER-Medicare linked database. Appl Health Econ Health Policy. 2009;7(1):31-41.

Buchanan A, Sugg Skinner C, Calingaert B, Schildkraut J, King R, Marcom K. Cancer genetic counseling in rural North Carolina oncology clinics: program establishment and patient characteristics. Community Oncol. 2009;6(2):70-7.

Britt DM, Cohen LM, Collins FL, Cohen ML. Cigarette smoking and chewing gum: response to a laboratory-induced stressor. Health Psychol. 2001 Sep 1;20(5):361-8.